China’s 2008 population accounts for 19.2% of the world’s population and 5% of the global gross domestic product (GDP). According to estimates and on a consistent double digit annual economic growth rate, China could become the fifth largest drug market by 2010–11 and the largest by 2050 (overtaking the US). Growth is mainly driven by ageing population, rising incomes, improving drug regulation by the State Food and Drug Administration (SFDA), maturing intellectual property rights (IPR), increasing medical insurance coverage of urban & rural residents and growing consumer demand for quality health care.

Chinese Hospital Pharmaceutical Market Outlook to 2014 provides a comprehensive coverage of the Chinese pharmaceutical market, market structure, pricing and regulation and includes detailed epidemiological analyses of the common risk factors. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Chinese hospital pharmaceutical market. Furthermore, it highlights the key developments in the healthcare system and R&D trends that may influence treatment sales, with a thorough analysis of the competitive dynamics of leading brands in order to enable the reader to identify growth trends, key drug classes and leading players through to 2014.

Key findings

The Chinese hospital pharmaceutical market in 2008 was valued at $20.3bn, registering a y-o-y growth of 37.8%, and is forecast to grow at a CAGR of 11.9% during 2008–14 period reaching 39.9bn in 2014.

Traditional Chinese Medicines (TCMs) continued to garner significant market share in 2008. Shu Xue Ning, Shu Xue Tong and Xing Nao Jing were the leading drugs with 2008 sales of $150m, $94m and $87m respectively.

The Chinese hospital pharmaceutical market is highly fragmented and comprises a number of traditional Chinese medicines among top selling products. The top 10 products in this market constituted a very small fraction of the overall market representing only 6.9% share or $1.3bn sales in 2008.

Pfizer led the Chinese hospital pharmaceutical market in 2008 posting $414m in sales at a y-o-y growth of 37%. Pfizer’s leading presence in this market has been attributed to the strong sales performance of Lipitor and Norvasc with 2008 sales of $62m and $58m at a y-o-y sales growth of 54.3% and 26.1% respectively.

Use this report to

- Develop insights for the Chinese hospital pharmaceutical market, healthcare system, pricing & regulation and detailed epidemiological status of the common risk factors in China

- Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges in China

- Gain up-to-date competitive intelligence across a wide-range of marketed products (along with Traditional Chinese Medicines), R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Chinese hospital pharmaceutical market

- Understand which indications have the greatest potential to provide franchise growth, and how pharmaceutical companies are attempting to exploit these opportunities

- Compare the franchises of top pharmaceutical players across major indications, and understand how market share of leading companies will change over the next 5 years through 2014

Key events

An essential drug list (EDL) to curb the rising drug prices in China. In a span of 3 years, the Chinese government will build an essential medicine system which will include a list of essential drugs (drugs/medicines that satisfy priority healthcare needs) that would be produced and distributed under government control and supervision. Such drugs will also be available at all retail drugstores and medical institutions.

Chinese government will deal with rural medical staff shortages under 2009–11 plan. Growing political pressure and criticism over drug safety issues in the past have led to the FDA becoming increasingly vigilant, resulting in fewer drugs being approved. The agency is currently suffering from a lack of funds and expert staff.

All villages in China will have a medical clinic in next 3 years. The government will support the construction of 2,000 hospitals at the county level to guarantee that each county has a hospital of national standard. Moreover, the government will also build or renovate around 3,700 community clinics and 11,000 medical centers in urban areas in next 3 years.

Amended healthcare reforms will strengthen the healthcare system in urban and rural areas. China will promote healthcare reform in 4 areas namely public health services, medical treatment, medical insurance and drug supply for both urban and rural residents. The government will provide education on disease prevention and control, healthcare for women and children, first aid, blood donation and family planning to both urban and rural residents. Efforts will also be made to improve the sanitation of living and working conditions for the entire population (both urban and rural) and to deal with all forms of pollution.

Discover

- What will be the major growth indications in the Chinese hospital pharmaceutical market over the period 2008–14?

- Which are the major companies (both multinational and domestic) in the Chinese hospital pharmaceutical market and how is their strategic outlook to 2014?

- Which products will be impacted by generic competitors over the period 2008–14?

- Which are the key Traditional Chinese Medicines (TCMs) in the Chinese hospital pharmaceutical market and their forecast through 2014?

- What will be the competitive landscape in cardiovascular, oncology, anti-infective and respiratory markets of Chinese hospital pharmaceutical market in 2014?

- How is the drug regulatory system structured in China?

- Which indications are forecast to have the highest levels of market potential over the period 2008–14?


Table of Contents



127 pages

Publication Date : July 2009